Protective Effects of Anti-IL17 on Acute Lung Injury Induced by LPS in Mice

Imagem de Miniatura
Arquivos
art_RIGHETTI_Protective_Effects_of_AntiIL17_on_Acute_Lung_Injury_2018.PDF (3.15 MB)
Citações na Scopus
42
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
SANTANA, Fernanda Paula Roncon
CRUZ, Maysa Mariana
ALONSO-VALE, Maria Isabel Cardoso
Citação
FRONTIERS IN PHARMACOLOGY, v.9, article ID 1021, 15p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: T helper 17 (Th17) has been implicated in a variety of inflammatory lung and immune system diseases. However, little is known about the expression and biological role of IL-17 in acute lung injury (ALI).We investigated the mechanisms involved in the effect of anti-IL17 in a model of lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. Methods: Mice were pre-treated with anti-IL17, 1h before saline/LPS intratracheal administration alongside non-treated controls and levels of exhaled nitric oxide (eNO), cytokine expression, extracellular matrix remodeling and oxidative stress, as well as immune cell counts in bronchoalveolar lavage fluid (BALF), and respiratory mechanics were assessed in lung tissue. Results: LPS instillation led to an increase in multiple cytokines, proteases, nuclear factor-kappa B, and Forkhead box P3 (FOXP3), eNO and regulators of the actomyosin cytoskeleton, the number of CD4+ and iNOS-positive cells as well as the number of neutrophils and macrophages in BALF, resistance and elastance of the respiratory system, ARG-1 gene expression, collagen fibers, and actin and 8-iso-PGF2 alpha volume fractions. Pre-treatment with anti-IL17 led to a significant reduction in the level of all assessed factors. Conclusions: Anti-IL17 can protect the lungs from the inflammatory effects of LPS-induced ALI, primarily mediated by the reduced expression of cytokines and oxidative stress. This suggests that further studies using anti-IL17 in a treatment regime would be highly worthwhile.
Palavras-chave
acute lung injury, inflammation mediators, interleukin 17, remodeling, oxidative stress
URI
https://observatorio.fm.usp.br/handle/OPI/29375
Referências
  1. Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
  2. Aristoteles LRCRB, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-52
  3. Barlow JL, 2011, CLIN EXP ALLERGY, V41, P1447, DOI 10.1111/j.1365-2222.2011.03806.x
  4. Barnes PJ, 2016, J ALLERGY CLIN IMMUN, V138, P16, DOI 10.1016/j.jaci.2016.05.011
  5. do Carmo MBB, 2016, DEV PSYCHOBIOL, V58, P1076, DOI 10.1002/dev.21441
  6. Blondonnet R, 2016, DIS MARKERS, DOI 10.1155/2016/3501373
  7. Boshier Piers R, 2013, J Breath Res, V7, P017118, DOI 10.1088/1752-7155/7/1/017118
  8. Camargo LD, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01835
  9. Castillo R L, 2015, Open Respir Med J, V9, P83, DOI 10.2174/1874306401509010083
  10. Caucheteux SM, 2017, MUCOSAL IMMUNOL, V10, P361, DOI 10.1038/mi.2016.54
  11. Defert O, 2017, EXPERT OPIN THER PAT, V27, P507, DOI 10.1080/13543776.2017.1272579
  12. Ding Q, 2017, ONCOTARGET, V8, P93704, DOI 10.18632/oncotarget.21474
  13. Elfsmark L, 2018, TOXICOL LETT, V282, P1, DOI 10.1016/j.toxlet.2017.10.007
  14. Erbel C, 2014, J IMMUNOL, V193, P4344, DOI 10.4049/jimmunol.1400181
  15. French BM, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12385
  16. Gasch M, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/182549
  17. Ge SW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085461
  18. Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447
  19. GONCALVESDEALBUQUE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/FIMMU.2017.01437
  20. Gonzalez-Lopez A, 2012, CRIT CARE, V16, DOI 10.1186/cc11224
  21. Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
  22. Hasegawa T, 2017, EUR CYTOKINE NETW, V28, P8, DOI 10.1684/ecn.2017.0390
  23. Hendrix AY, 2017, PROG MOL BIOL TRANSL, V148, P1, DOI 10.1016/bs.pmbts.2017.04.004
  24. Hergrueter AH, 2011, AM J PHYSIOL-LUNG C, V300, pL512, DOI 10.1152/ajplung.00023.2011
  25. Nguyen H, 2013, CARDIOVASC RES, V97, P696, DOI 10.1093/cvr/cvs422
  26. Hsu D, 2016, INFECT IMMUN, V84, P2410, DOI 10.1128/IAI.00284-16
  27. Huang GH, 2012, CELL MOL IMMUNOL, V9, P287, DOI 10.1038/cmi.2012.10
  28. Bittencourt-Mernak MI, 2017, AM J PHYSIOL-LUNG C, V312, pL217, DOI 10.1152/ajplung.00444.2015
  29. Kaneko-Kawano T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039269
  30. Lancas T, 2006, J APPL PHYSIOL, V100, P1610, DOI 10.1152/japplphysiol.00828.2005
  31. Leitinger N, 2001, FASEB J, V15, P1254
  32. Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
  33. Li TJ, 2017, MOL MED REP, V16, P2225, DOI 10.3892/mmr.2017.6837
  34. Lo CY, 2018, INT J CHRONIC OBSTR, V13, P1135, DOI 10.2147/COPD.S161257
  35. Martins-Olivera BT, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/5346574
  36. Mikacenic C, 2016, CRIT CARE MED, V44, P496, DOI 10.1097/CCM.0000000000001409
  37. Modrykamien Ariel M, 2015, Proc (Bayl Univ Med Cent), V28, P163
  38. National Institutes of Health, 2011, GUIDE CARE USE LAB A
  39. O'Dwyer DN, 2016, AM J PHYSIOL-LUNG C, V311, pL590, DOI 10.1152/ajplung.00221.2016
  40. Pigati PA, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0073-4
  41. Pinheiro NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120441
  42. Possa SS, 2012, AM J PHYSIOL-LUNG C, V303, pL939, DOI 10.1152/ajplung.00034.2012
  43. Prado CM, 2006, AM J RESP CELL MOL, V35, P457, DOI 10.1165/rcmb.2005-0391OC
  44. Prado Carla M, 2011, ISRN Allergy, V2011, P832560, DOI 10.5402/2011/832560
  45. Prause O, 2004, THORAX, V59, P313, DOI 10.1136/thx.2003.008854
  46. RighettI RF, 2014, RESP PHYSIOL NEUROBI, V192, P134, DOI 10.1016/j.resp.2013.12.012
  47. Riva DR, 2008, CRIT CARE MED, V36, P1900, DOI 10.1097/CCM.0b013e3181760e5d
  48. Rosadini CV, 2017, CURR OPIN IMMUNOL, V44, P14, DOI 10.1016/j.coi.2016.10.005
  49. Saddy F, 2010, INTENS CARE MED, V36, P1417, DOI 10.1007/s00134-010-1808-6
  50. Sakaguchi R, 2016, INT IMMUNOL, V28, P233, DOI 10.1093/intimm/dxv070
  51. Scholz H, 2003, CARDIOVASC RES, V59, P945, DOI 10.1016/S0008-6363(03)00538-8
  52. Sharanek A, 2016, SCI REP-UK, V6, DOI 10.1038/srep24709
  53. Theodoro OA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020403
  54. Vieira RP, 2007, AM J RESP CRIT CARE, V176, P871, DOI 10.1164/rccm.200610-1567OC
  55. Villegas L, 2014, J PULM RESP MED, V4, P194, DOI 10.4172/2161-105X.1000194
  56. WEIBEL ER, 1963, LAB INVEST, V12, P131
  57. WEIBEL ER, 1979, AM J ROENTGENOL, V133, P1020, DOI 10.2214/ajr.133.6.1021
  58. Witter AR, 2016, J IMMUNOL, V197, P1557, DOI 10.4049/jimmunol.1600599
  59. Xu H, 2018, CELL RES, V28, P139, DOI 10.1038/cr.2017.156
  60. Yanagisawa H, 2017, AM J PHYSIOL-LUNG C, V312, pL122, DOI 10.1152/ajplung.00301.2016
  61. Zhao GM, 2017, INT IMMUNOPHARMACOL, V46, P80, DOI 10.1016/j.intimp.2017.02.017
  62. Zizzo G, 2013, J IMMUNOL, V190, P5237, DOI 10.4049/jimmunol.1203017

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/20